GSK's renewed oncology push yields new approvals and trial data

In the past week, GSK secured regulatory clearance for a cancer therapy targeting an additional tumor type and presented initial findings from a global study of an innovative chemotherapy candidate. The company also showcased a licensed oncology drug during a presidential session at a leading cancer congress in Madrid. A further approval for a lung-cancer treatment is expected in the coming weeks, marking a rapid resurgence after GSK exited oncology a decade ago.